SINGAPORE – February 25, 2026 – (SeaPRwire) – Domoa Private Limited today announced a strategic initiative to accelerate the adoption of 3D concrete printing (3DCP) across Singapore and the broader Southeast Asian real estate market, positioning the company at the forefront of next-generation construction delivery in the region.
The technology is no longer experimental. On construction sites from Dubai to Denmark, and from Texas to the Netherlands, 3D concrete printing has demonstrated that it works, scales, and expands what is possible in real estate development. Yet despite Southeast Asia being one of the world’s most dynamic construction markets, adoption has remained limited. Domoa is moving to change that.
A Region Built for 3DCP — That Has Yet to Embrace It
Southeast Asia presents one of the most compelling untapped opportunities for 3D concrete printing anywhere in the world. The region is building at pace — luxury resorts, residential clusters, villa developments, boutique hospitality projects — across terrains and climates that demand smart, adaptable construction solutions. Labour costs are rising. Sustainability pressures are intensifying. Clients are more sophisticated than ever and increasingly unwilling to accept the delays, waste, and inconsistency that conventional construction routinely delivers.
3DCP directly addresses these pressures. The technology can reduce build timelines by up to 50 percent, significantly lower material waste, and achieve structural precision beyond traditional manual processes. It enables complex geometries — curved walls, sculpted facades, and organic forms — that would be prohibitively expensive to realise through conventional construction methods. At the same time, 3DCP offers the potential for a lower carbon footprint compared to standard concrete construction.
While the technology has been proven internationally, implementation expertise in Southeast Asia has remained limited. Moving from proof-of-concept to delivered, high-quality projects requires coordinated design, technical integration, and disciplined execution. Domoa was established to bridge that gap.
Domoa’s Mission: Make 3DCP the Standard, Not the Exception
Domoa’s core objective is to embed 3D concrete printing into the mainstream of Singapore’s real estate development, project by project. The company assumes full responsibility for design management on low-rise developments across the region, integrating 3DCP as the primary construction methodology and optimising each project around the technology’s unique strengths.
Working with 3D printing-affiliated operators whose industrial-scale printers represent the cutting edge of the sector — alongside architects, developers, and local partners in Singapore — Domoa oversees the entire design and implementation lifecycle. Projects are structured from inception to maximise the advantages of 3DCP: optimised structural forms, efficient material deployment, accelerated construction schedules, and enhanced architectural freedom.
The company focuses on luxury low-rise developments, including villas, boutique resorts, residential clusters, and select commercial projects, in markets where adoption conditions are favourable and where its involvement can materially accelerate uptake.
Design Optimised for the Technology — and for the People Inside It
Adopting 3D concrete printing is not simply a matter of replacing one construction technique with another. To fully realise its potential, projects must be designed from the outset with 3DCP in mind. This is where Domoa’s design management expertise becomes central.
Each project led by Domoa is conceived to leverage the strengths of large-scale 3D printing: fluid geometries, continuous structural forms, material efficiency, and high-precision execution. Beyond structural performance, the company integrates passive wellness principles into its design framework — including natural ventilation strategies, solar orientation optimisation, thermal mass utilisation, and biophilic design connections.
By aligning advanced construction technology with human-centred architectural thinking, Domoa aims to deliver developments that are not only faster and more sustainable to build, but also healthier, more comfortable, and more responsive to their natural surroundings.
About Domoa
Domoa Development is Singapore’s first company dedicated to integrating large-scale 3D printing into luxury real-estate development. It is a next-generation real estate development company dedicated to creating resorts that inspire well-being and respect the environment.
Media contact
Brand: Domoa
Contact: Media team
Email: info@domoadevelopment.com
Website: https://www.domoadevelopment.com/
HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by the National Medical Products Administration of China (the “NMPA”), pursuant to which, the supplemental application to expand the age range of applicable population of the Company’s Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the “MCV4”, trade name: Menhycia (R)) from “children aged from 3 months to 3 years old (47 months)” to “children aged from 3 months to 6 years old (83 months)” has been approved by NMPA.This approval marks an important step forward, underscoring the public health impact of Menhycia (R) while also strengthening its long-term commercial prospects. Under China’s current national immunization schedule, the final pre-school dose of meningococcal vaccination is administered at six years of age. For a long time, multivalent conjugate vaccine options for children over age three have been relatively limited in the domestic market. The newly approved expansion of the eligible age range helps address this gap, providing broader and more appropriate vaccination options for this population.At the same time, the broader eligible population is expected to further unlock Menhycia (R)’s commercialization prospects, and lay a more solid foundation for the product’s promotion and strategic rollout in international markets.Notably, CanSinoBIO issued its Results Forecast For The Year 2025 recently. Forecasting total revenue of RMB 1.04–1.08 billion, a year-on-year increase of 22.88% to 27.61% and net profit attributable to the shareholders of RMB 24.5–29.0 million—marking a return to profitability. The company noted that Menhycia (R), China’s first domestically developed quadrivalent meningococcal conjugate vaccine, continues to drive sustained revenue growth under its innovation-led commercialization strategy. This also signifies that the company is now reaping the commercial benefits of its early investments in vaccine innovation.Leveraging its proprietary platform, first-mover advantages, and accelerating global expansion, the age expansion of Menhycia (R) is expected to further strengthen CanSinoBIO’s competitive position while providing new momentum for sustainable growth. As product coverage broadens and international commercialization advances, the company is well-positioned to enter a new phase of long-term growth. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 25, 2026 - (ACN Newswire via SeaPRwire.com) – Shoucheng Holdings Ltd. (00697.HK) drew market attention on Tuesday after its share price experienced volatility alongside certain shareholding adjustments, prompting discussion among investors. A review of the company’s recent disclosures, publicly available trading data and evolving market structure suggests the movement largely reflects short-term capital repositioning rather than any change in fundamentals.Market participants indicated that during the recent market pullback, several international long-only investors executed strategic allocations through block trades and negotiated transactions, facilitating an orderly transition in the company’s shareholder base. Observers said the shift — characterized by a rotation from short-term trading positions to longer-duration institutional capital — could help smooth liquidity fluctuations while enhancing the stability and quality of the shareholder structure.From a capital-markets perspective, the entry of long-term funds typically signals recognition of a company’s medium- to long-term growth trajectory and value realization capacity. Such positioning is widely viewed as laying a firmer foundation for future valuation normalization.Historically, shareholder base optimization and rebalancing often coincide with the stage at which a company’s strategic transformation begins to translate into tangible results. The latest restructuring underscores a more proactive stance by international capital in participating in Shoucheng’s growth story, endorsing its strategic shift from a traditional asset-management platform to a builder of hard-technology industrial ecosystems. The resonance between capital flows and industrial logic is expected to reinforce market confidence in the company’s long-term value proposition.Foreign institutional buying during periods of market weakness reflects confidence in what analysts describe as a structural transformation of Shoucheng’s fundamentals. The company has transitioned from a conventional asset-management model into what it terms an “industrial ecosystem builder.” Through a differentiated “capital + scenario + operations” framework, Shoucheng has established a closed-loop ecosystem, particularly in the robotics sector, where its forward-looking investments have positioned it as a bellwether for hard-technology exposure in Hong Kong equities.The year 2026 is widely regarded by the market as a pivotal window for the accelerated commercialization of embodied artificial intelligence and humanoid robotics. Shoucheng’s systematic early-stage positioning across the robotics value chain is now entering a concentrated realization phase, with portfolio returns demonstrating notable strength.Core projects have generated substantial premiums. Early and concentrated investments in leading companies such as Zibianliang Technology and Unitree Robotics have delivered significant mark-to-market gains. As high-profile holdings including Unitree advance toward initial public offerings, Shoucheng’s equity stakes are poised to transition from unrealized book gains to realized returns and dividend contributions, providing tangible earnings accretion at the listed-company level.Further attention has focused on the high-profile appearance of robotics firms including Unitree Robotics, Galaxy General Robotics and Songyan Dynamics at the 2026 Lunar New Year Gala broadcast by China Central Television, the Year of the Horse edition. Their demonstrations showcased breakthroughs in embodied intelligence, complex motion control and human-machine interaction. The visibility not only strengthened public awareness but also signaled that large-scale commercial deployment may be imminent. As an important early-stage investor in these enterprises, Shoucheng stands to benefit indirectly from both heightened sector visibility and an accelerated commercialization cycle, potentially catalyzing valuation re-rating.Analysts said Tuesday’s trading activity is likely to result in a more diversified shareholder mix. The participation of long-duration international capital may enhance the stock’s global liquidity profile and governance transparency expectations, while also broadening the company’s access to cross-border industrial and strategic resources to support future expansion.Market experience suggests that when a company’s fundamentals enter an upward cycle and structural uncertainties gradually dissipate, shareholder optimization can serve as a catalyst for valuation recovery. According to analysts, the latest rotation in holdings represents a strategic rebalancing of the capital structure, easing short-term supply pressure as the company approaches a value-realization phase.Taken together, Shoucheng appears to be navigating a convergence of three inflection points. First is an industrial inflection, as embodied AI and robotics commercialization accelerate. Second is a capital inflection, with investment projects entering a concentrated realization period. Third is a structural inflection, marked by the entry of long-term international capital and the optimization of the shareholder base.Amid the alignment of global capital endorsement and industrial value dividends, the company’s valuation framework is shifting from that of a traditional asset manager toward that of a hard-technology industrial platform. As industrial deployment advances and investment returns crystallize, market recognition of Shoucheng’s role as an infrastructure builder for the intelligent era may deepen, suggesting that the process of long-term value redefinition has entered a substantive phase. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年2月25日 - (亚太商讯 via SeaPRwire.com) - 今日，市场关注到首程控股（00697.HK）股价出现一定波动，叠加个别股份变动安排，引发部分投资者讨论。综合公司近期公告、公开行情数据及市场结构变化情况来看，相关波动更多体现为阶段性资金博弈。在资本结构持续优化、产业主线逻辑清晰的背景下，公司基本面未发生实质性变化。市场人士透露，在近期市场调整过程中，部分国际长线资金通过协议及大宗方式完成战略性布局，实现了筹码结构的有序转换。相关观点认为，这种"短期筹码向长期资本转移"的过程，有助于平滑阶段性流动性波动，同时提升股东结构的稳定性与质量。从资金属性看，长线资本的进入往往意味着对公司中长期成长路径与价值兑现能力的认可，为后续估值修复奠定更加坚实的资金基础。从资本市场运行规律来看，当企业战略转型逐步进入成果兑现阶段时，股东结构的优化与再平衡往往同步发生。本轮结构调整所释放的核心信号在于，国际资金正以更为积极的姿态参与公司成长进程，认可其由传统资产管理平台向"硬科技产业生态构建者"升级的战略方向。这种资本与产业逻辑的共振，有助于强化市场对公司长期价值的认知与定价信心。外资机构的逆势买入，其逻辑支撑源于首程控股基本面的深刻蜕变。公司正从传统的资产管理平台，成功向"产业生态构建者"转型。通过独特的"资本+场景+运营"三维模式，首程控股已构建起闭环生态，特别是在机器人赛道的前瞻性布局，已使其成为港股硬科技投资的标杆。2026年被市场普遍视为具身智能与人形机器人商业化加速落地的重要时间窗口。首程控股前期在机器人赛道的系统性布局，正在进入集中收获期，机器人赛道整体投资回报表现亮眼：核心项目实现高溢价： 依托对自变量科技、宇树科技等领军企业的早期重仓已实现显著账面增值，随着宇树科技等明星项目正式开启IPO冲刺，首程控股持有的股权将迎来从"账面浮盈"向"现金分红"的实质性跨越，持续增厚上市公司利润。此外，值得关注的是，在2026年马年央视春晚舞台上，宇树科技、银河通用、松延动力等机器人企业集体亮相，展示了具身智能技术在复杂动作控制与人机交互方面的突破。这不仅强化了公众认知，也标志着相关企业已进入规模化应用前夜。作为上述企业的重要早期布局方，首程控股间接受益于产业热度与商业化进程提速带来的估值重估。市场分析人士表示，今日的市场交易将促使公司股东结构更趋多元化。国际长线资金的进入，一方面提升了股票的全球流动性基础与治理透明度预期，另一方面也为未来产业扩张提供更广泛的资源协同空间。从市场经验看，当企业基本面处于上行周期且结构性不确定性逐步消除时，股东结构的优化往往成为估值修复的重要触发因素。分析人士指出，本轮筹码调整本质上是资本结构的战略再平衡，为公司进入价值兑现周期扫清短期供给压力。综合来看，首程控股当前处于三重拐点叠加阶段，首先是产业拐点—具身智能与机器人商业化加速；其次是资本拐点—投资项目进入集中兑现期；再次是结构拐点—国际长线资本入场优化股东结构。在国际资金认可与产业价值红利共振之下，公司估值逻辑正从"传统资管估值框架"向"硬科技产业平台估值框架"切换。随着产业落地与资本回报逐步兑现，市场对于首程控股作为"智能时代产业基础设施构建者"的认知将进一步强化，其长期价值重塑进程或已进入实质性阶段。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
Kawasaki, Gunma, Japan, Feb 25, 2026 - (JCN Newswire via SeaPRwire.com) - BEISIA CO., LTD. and Fujitsu Limited today announced that both companies have begun introducing and operating Fujitsu's Advanced Operation & Management offering for digitalizing stores and improving labor productivity at Beisia stores. This solution, part of Fujitsu’s Uvance business model, is being used to automate the temperature management of refrigerator and freezer facilities within stores. The companies plan to implement the solution in all 138 Beisia stores across Japan by May 2026.Introduction of the solution commenced in December 2025This initiative will streamline operations for store employees in complying with HACCP requirements(1), enhancing product freshness management and reducing food loss by providing alert notifications when abnormalities exceeding set thresholds are detected.Under its Uvance business model, which addresses societal challenges, Fujitsu will leverage the knowledge and experience gained from implementing Advanced Operation & Management at Beisia to drive the digitalization of stores through data and AI, enhance labor productivity and promote sustainable store operations.OverviewPrior to the full-scale rollout, Beisia conducted a practical verification of the solution at its Beisia Foods Park Takasaki Kuragano store (Takasaki City, Gunma Prefecture). After confirming the effectiveness of temperature data acquisition and management, as well as the efficiency gains for employees, Beisia decided to implement the solution across all its stores, with sequential deployment beginning in December 2025.Fujitsu's Advanced Operation & Management is a solution that visualizes data acquired from various IoT sensors in real-time. A key feature is its rapid deployment and operation through the attachment of IoT sensors to existing equipment, without dependency on specific hardware.At Beisia, IoT sensors attached to refrigeration and freezing equipment throughout the stores will extract and visualize temperature information in real-time. This eliminates the need for manual inspection and recording by store employees, significantly reducing their workload.Moreover, when abnormalities exceeding thresholds or conditions are detected, alerts are promptly sent to the store's operational communication tools. This enables quicker initial responses to anomalies, strengthening product freshness management, and reducing food loss. Additionally, both headquarters and individual stores can access the same real-time information via a dashboard, facilitating centralized management of information from multiple stores and supporting overall store operation optimization.In Japan, the revised Food Sanitation Act(2) mandates the implementation of HACCP, an international standard for food hygiene management, for all food-related businesses. In the supermarket retail industry, thorough temperature management is crucial for product freshness and consumer trust. However, with a severe labor shortage, streamlining inspection and recording tasks has become an urgent issue.Previously, Beisia stores manually recorded temperatures twice a day for an average of 150 refrigeration and freezing units per store, posing a significant workload for employees. Against this backdrop, Beisia decided to introduce a solution to automate temperature management for its in-store refrigeration and freezing equipment.Figure 1: Overview of Fujitsu's IoT Visualization SolutionFigure 2: IoT Sensor installed in a Beisia store freezer(1) HACCP (Hazard Analysis and Critical Control Point):A food hygiene management method that ensures product safety by identifying and managing critical control points throughout the entire food production process, from raw material reception to product shipment, to eliminate or reduce hazards such as food poisoning bacteria contamination and foreign object mixing.(2) Revised Food Sanitation Act:A law designed to ensure food safety in response to changes in the food environment and globalization. Revised in 2018, it mandated HACCP implementation.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
SHENZHEN, Feb 24, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product’s review process for marketing approval in the AD indication.
Impressive phase III trial data in AD
Its Priority Review is expected to accelerate its NDA approval
Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product’s expansion into multiple therapeutic areas.
Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD.
Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001).
Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated.
Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date.
Building an integrated AD solution,
strengthening Dermavon’s leadership in dermatology
AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.
Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care.
Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s market competitiveness and brand influence in the field of skin health.
More Information About Ruxolitinib Phosphate Cream
Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].
The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).
Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/
